$TSHA News

Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target

Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies Announces Multiple Presentations Highlighting TSHA-102 Program In Clinical Evaluation For Rett Syndrome At 2026 IRSF Rett Syndrome Scientific Meeting

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies Commences $200M Common Stock Offering

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome - Slideshow

BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14

B of A Securities Maintains Buy on Taysha Gene Therapies, Raises Price Target to $10

Citizens Maintains Market Outperform on Taysha Gene Therapies, Raises Price Target to $11

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

Taysha Advances Rett Syndrome Programme as Pivotal Trial Enrollment Completes (TSHA)

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

Taysha Gene Therapies Completes Dosing In REVEAL Prival Study Of 17 Females In Developmental Plateau Population Of Rett Syndrome

Taysha Gene Therapies (TSHA) Stock Looks Undervalued After Sharp Three Year Recovery

Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now?

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies: Shortened Timeline Increases The Potential

Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026